Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study-Reference-Cited by-同舟云学术

Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study

Published:2023-12 Issue: Volume: Page:
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Li Xingzhi,Wang Xiaobo,Bai Tao,Chen Jie,Lu Shaolong,Wei Tao,Tang Zhihong,Zhao Guilin,Lu Huaze,Li Lequn,Wu Feixiang

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. Hepatocellular carcinoma;Villanueva;N Engl J Med,2019

2. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma;Zhong;Ann Surg,2014

3. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT;Yin;J Hepatol,2014

4. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors;Arita;J Hepatobiliary Pancreat Sci,2022

5. Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response;Yang;Front Immunol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy;Current Oncology;2024-01-19